Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- 50% Price Rule, Unifying Price Brackets Starters of Next Generic Price Revision Discussions: Ministry Official
July 15, 2014
- MHLW Panel to Elaborate Proposed Scheme to Broaden Drug Development Requests
July 15, 2014
- Editor’s Pick: Five Healthcare News Headlines for June 30 - July 11
July 14, 2014
- Revised PAL to Go Live on November 25: Ministry Exec
July 14, 2014
- Science Ministry’s Updated Guidelines to Require Research Data Preservation
July 14, 2014
- Draft Policy on Resource Allocation Focuses Funding on 9 Fields of Healthcare R&D
July 14, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 1: TRI Director Fukushima
July 14, 2014
- Unami Tapped as New Budget Examiner for Health Finances
July 11, 2014
- PFSB Announces Final Draft of Drug Interaction Guidelines
July 11, 2014
- Utsunomiya to Move to National Center for Global Health and Medicine
July 10, 2014
- MHLW Orders Revisions of Precaution Statements for a Number of Drugs Including Forteo and Paxil
July 10, 2014
- MHLW Releases Report on Medical Database Project
July 9, 2014
- Doctors at Ryukaikon Council Request Mandatory Inclusion of Expiry Dates in Product Barcodes
July 8, 2014
- MHLW OKs IFN-Free Hepatitis C Treatments
July 8, 2014
- Keiya Iida of METI to Be First “Councilor for the Promotion of Pharmaceutical and Related Industries”: MHLW
July 8, 2014
- Kiyohito Nakai to Be Appointed Pharmaceutical Management Director
July 8, 2014
- Ryukaikon Council Member Requests Rewards instead of Penalties for Early Delivery Price Settlements
July 7, 2014
- Initiatives for Drug Distribution Improvement Advanced in FY2013: Ryukaikon Council
July 7, 2014
- Yuji Kanda to Head PFSB, Kazuo Futagawa to Head HPB Following Reshuffling of MHLW Top Officials
July 7, 2014
- MHLW to Issue Business Practice Improvement Order to Novartis for Violation of ADR Reporting Requirement
July 4, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…